Forsta AP Fonden Sells 1,200 Shares of Insulet Co. (NASDAQ:PODD)

Forsta AP Fonden trimmed its position in shares of Insulet Co. (NASDAQ:PODD) by 3.1% during the 4th quarter, Holdings Channel.com reports. The institutional investor owned 37,500 shares of the medical instruments supplier’s stock after selling 1,200 shares during the quarter. Forsta AP Fonden’s holdings in Insulet were worth $9,790,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also recently modified their holdings of PODD. Blue Trust Inc. increased its stake in shares of Insulet by 84.1% in the 3rd quarter. Blue Trust Inc. now owns 127 shares of the medical instruments supplier’s stock worth $30,000 after purchasing an additional 58 shares in the last quarter. Venturi Wealth Management LLC lifted its position in shares of Insulet by 633.3% during the 3rd quarter. Venturi Wealth Management LLC now owns 154 shares of the medical instruments supplier’s stock valued at $36,000 after buying an additional 133 shares in the last quarter. TD Private Client Wealth LLC grew its stake in shares of Insulet by 32.6% during the 3rd quarter. TD Private Client Wealth LLC now owns 228 shares of the medical instruments supplier’s stock valued at $53,000 after acquiring an additional 56 shares during the period. Friedenthal Financial purchased a new stake in Insulet in the 4th quarter worth approximately $57,000. Finally, Versant Capital Management Inc lifted its holdings in Insulet by 106.1% during the fourth quarter. Versant Capital Management Inc now owns 305 shares of the medical instruments supplier’s stock valued at $80,000 after purchasing an additional 157 shares in the last quarter.

Insider Transactions at Insulet

In other news, CAO Lauren Budden sold 915 shares of the company’s stock in a transaction dated Tuesday, December 10th. The shares were sold at an average price of $275.62, for a total transaction of $252,192.30. Following the transaction, the chief accounting officer now owns 5,733 shares in the company, valued at $1,580,129.46. This represents a 13.76 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, EVP Eric Benjamin sold 12,394 shares of Insulet stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $280.00, for a total transaction of $3,470,320.00. Following the completion of the sale, the executive vice president now owns 11,383 shares of the company’s stock, valued at $3,187,240. This trade represents a 52.13 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 0.47% of the company’s stock.

Insulet Trading Up 1.1 %

Shares of NASDAQ PODD opened at $280.03 on Friday. The business has a fifty day moving average price of $268.38 and a 200 day moving average price of $237.41. Insulet Co. has a 1-year low of $160.19 and a 1-year high of $286.39. The company has a debt-to-equity ratio of 1.21, a current ratio of 3.68 and a quick ratio of 2.80. The stock has a market capitalization of $19.64 billion, a P/E ratio of 47.95, a price-to-earnings-growth ratio of 3.50 and a beta of 1.22.

Insulet (NASDAQ:PODD) last issued its quarterly earnings data on Thursday, November 7th. The medical instruments supplier reported $0.90 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.77 by $0.13. The firm had revenue of $543.90 million for the quarter, compared to the consensus estimate of $518.50 million. Insulet had a net margin of 21.22% and a return on equity of 27.98%. During the same quarter in the previous year, the firm earned $0.71 EPS. Equities research analysts expect that Insulet Co. will post 3.22 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on PODD shares. TD Cowen increased their price objective on shares of Insulet from $264.00 to $324.00 and gave the stock a “buy” rating in a research note on Friday, January 3rd. Citigroup raised their price target on Insulet from $283.00 to $310.00 and gave the company a “buy” rating in a report on Wednesday, December 11th. Raymond James upped their price objective on Insulet from $213.00 to $260.00 and gave the stock an “outperform” rating in a research note on Monday, October 14th. Morgan Stanley lifted their target price on Insulet from $234.00 to $317.00 and gave the company an “overweight” rating in a research note on Monday, November 11th. Finally, BTIG Research increased their price objective on shares of Insulet from $260.00 to $270.00 and gave the company a “buy” rating in a report on Friday, November 8th. Three investment analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $272.81.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.